Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
About This Webinar
The scale-X bioreactors range and the NevoLine platform represent the next generation of viral manufacturing technologies. These technologies capitalize on the principles of process intensification, automation and chaining to achieve high-performance operations in a miniaturized and integrated process. The design of these technologies offer a range of configurations supporting gene therapies development with a drastic reduction of CAPEX and OPEX as well as final cost of goods. The comprehensive aspect of the scale-X bioreactor range provide to gene therapy developers a solution ensuring batch-to-batch reproducibility allowing a seamless scalability from R&D to commercial phases.
Language:
English
Who can attend? Everyone
Featured Presenters
Sales Manager CIS & EMEA
Sales Manager at Univercells Technologies is dedicated to improving production of vaccines and innovative gene therapies. Holds a MSc degree in biotechnology from the Warsaw University of Life Sciences.
Manager Application & Technical Sales
Bioprocess Consultant specialized in Process Development & scale-up in Gene Therapy and vaccine applications. 5 years experience in Europe and Asia, Dipl.-Ing in Bioprocess Engineering from University of Karlsruhe.
Head of Sales
A sales professional focused on the Biotech industry, leading business development, growth and long-term cooperation. Experience in research and development and management allows for a deep understanding of the customer structure, offering added value.
Sales Manager
Extensive small and large company business development and sales experience in product development and service companies in the pharmaceutical and biotechnology industries. For the past 10 years I have been involved in the commercialization of fixed-bed bioreactors for viral vector and vaccine production.
Hosted By
The full session archive, available exclusively for attendees of the American Society of Gene & Cell Therapy's 23rd Annual Meeting, May 12-15, 2020.
Documents